ALCAM and cancer: This has been the case for many widely studied targets therapies in non-small lung cancer cells (e.g., EGFR and ROS1 mutations and ALK translocations) and several surface cell receptors in small cancer lung cells (e.g., PCRs, CXCR4, GLUT1, PETA/CD151, ALCAM/CD166, IGF1R and FGFRs, NCAM/CD56, RTK, ASCL1, SOX2, 4, and 11, OCT4, NANOG, PAX5, MYC) [38,39].